I said something in my last post that probably did not make sense. Maybe this will clarify.A few years ago another company had full rights and research ( and financial ) responsibility to move 188 along. They were producing sound and numerous studies with good , respectable results. But they were forced to close doors on the entire program due to finances. Really tricky business for a newer company to be so on the cutting edge, and less experienced. The lead researcher of that comp, with the product 188, came over to MAST( which at the time was listed under their old name). Correct me if I am stating it inaccurately. That was when MAST apparently took over and got behind the 188 seeing huge potential and having followed it well, over some time.My point is that this company MAST , does surely look back on the financial dilemmas of another very respectable company's intentional laboratory and eventual loss, and must move forward so nimbly. Required dilution is not pretty. Just look at what happened with NVAX TODAY. I am equally proud of THEIR endeavors to continue very needed programming /studies in the face of being yet too young to compete with the finance benefits of the big pharmas , (who are snagging big and secure bucks.) we must wait our turn to be recognized and then biggy heads will be craning their necks , due to the strength, potential and versatile utility of such novel and creative platforms.Already happening. Not an advisor but seeing a clearer perspective daily. All IMO. If I stated anything in error, please do us the favor of correcting me. Thankyou
News 
Market Data 
Discover 
